Drug intelligence / Profile preview

VDO

Development stage: Unknown
Lead developer: Yung Shin Pharmaceutical Industry
Modality: Small Molecules
Administration: Topical

Overview

VDO is a topical pharmaceutical drug developed by Yung Shin Pharm. Ind. Co., Ltd. It is formulated as a gel for the treatment of Herpes Simplex Labialis. The drug exhibits both antiviral and anti-inflammatory properties, aiming to shorten viral replication and alleviate associated pain and inflammation caused by the herpes virus.

Other names: VDO gel

Targets

PTGS2 (Prostaglandin-Endoperoxide Synthase 2)NaV (Voltage-gated sodium channels)PGHS-1 (Prostaglandin G/H Synthase 1)

Beyond the preview

Go deeper on VDO.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VDO.

Explore the full profile